Durable Response to Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma With Extensive Gluteal and Sacral Bone Infiltration: A 12-Month Case

晚期皮肤鳞状细胞癌伴广泛臀骶骨浸润患者对西米普利单抗治疗的持久反应:一例12个月的病例报告

阅读:1

Abstract

Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy, which, in its advanced stages, may involve regional lymph nodes and osseous structures, resulting in poor prognosis. Massive tumor infiltration of the sacrum and pelvic bones is rare and typically associated with limited treatment options and unfavorable outcomes. We present the case of a 59-year-old male with advanced cSCC involving the gluteal region, sacrum, pelvic lymph nodes, and bones. As part of a personalized treatment approach, the patient received a combination of cemiplimab, a PD-1 checkpoint inhibitor, and denosumab for bone protection. Despite the aggressive nature and anatomical complexity of the disease, the patient demonstrated a marked and durable clinical response, with radiographic evidence of partial metabolic regression on PET/CT (SUVmax reduction from 9.87 to 6.37), resolution of sacral pain, and full recovery of ambulatory function. No serious immune-related toxicities were observed. This case illustrates the potential of integrating immunotherapy with supportive bone-targeted therapy to achieve meaningful disease control in rare presentations of bone-invasive cSCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。